Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease -: Evidence for antioxidant and antiinflammatory effects

被引:131
作者
Heitzer, Thomas
Rudolph, Volker
Schwedhelm, Edzard
Karstens, Manuela
Sydow, Karsten
Ortak, Michelle
Tschentscher, Peter
Meinertz, Thomas
Boeger, Rainer
Baldus, Stephan
机构
[1] Univ Herzzentrum Hamburg, Med Klin 3, Abt Kardiol & Angiol, D-20246 Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Inst Klin Chem, Inst Expt & Klin Pharmaol, D-20246 Hamburg, Germany
关键词
clopidogrel; endothelial function; nitric oxide; platelets; coronary artery disease;
D O I
10.1161/01.ATV.0000225288.74170.dc
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Platelet stimulation and activation are known not only as prerequisite of clot formation but are increasingly recognized as important contributors to inflammation and vascular injury. The present study in patients with symptomatic coronary disease investigated whether platelet adenosine diphosphate receptor blockade by clopidogrel exerts beneficial effects on endothelial nitric oxide bioavailability, oxidative stress, and/or inflammatory status. Methods and Results - One hundred three consecutive patients with symptomatic coronary disease and long-term aspirin therapy were studied. Endothelium-dependent and -independent vasodilation was determined measuring forearm blood flow (FBF)-responses to acetylcholine with and without NG-monomethyl-L-arginin (L-NMMA) and sodium nitroprusside, by using venous occlusion plethysmography. Patients were randomized to receive additional treatment with clopidogrel or placebo. Vascular function tests were repeated after 5 weeks and showed significant improvement of acetylcholine-induced vasodilatation and L-NMMA responses in the clopidogrel-added group (max. FBF from 9.8 +/- 0.3 to 14.7 +/- 0.4; L-NMMA-response from 3.7 +/- 0.1 to 6.8 +/- 0.3 mL/100 mL/min). In contrast, no significant changes were observed in the placebo group. Sodium nitroprusside - induced vasodilation was not changed in either group. Urinary excretion of 8-iso-prostaglandin F2 alpha and plasma levels of hsCRP, sCD40L, and RANTES were reduced in patients on additional treatment with clopidogrel, but not in patients on placebo. Conclusions - Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects.
引用
收藏
页码:1648 / 1652
页数:5
相关论文
共 28 条
[1]   Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina -: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].
Aukrust, P ;
Müller, F ;
Ueland, T ;
Berget, T ;
Aaser, E ;
Brunsvig, A ;
Solum, NO ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
CIRCULATION, 1999, 100 (06) :614-620
[2]   Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release [J].
Chakrabarti, S ;
Clutton, P ;
Varghese, S ;
Cox, D ;
Mascelli, MA ;
Freedman, JE .
THROMBOSIS RESEARCH, 2004, 113 (3-4) :225-233
[3]   Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease [J].
Fichtlscherer, S ;
Rosenberger, G ;
Walter, DH ;
Breuer, S ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2000, 102 (09) :1000-1006
[4]   Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease [J].
Fichtlscherer, S ;
Breuer, S ;
Heeschen, C ;
Dimmeler, S ;
Zeiher, AM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (01) :44-49
[5]   Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization [J].
Furman, MI ;
Krueger, LA ;
Linden, MD ;
Barnard, MR ;
Frelinger, AL ;
Michelson, AD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2319-2325
[6]   Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease [J].
Heitzer, T ;
Schlinzig, T ;
Krohn, K ;
Meinertz, T ;
Münzel, T .
CIRCULATION, 2001, 104 (22) :2673-2678
[7]   Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease [J].
Heitzer, T ;
Ollmann, I ;
Köke, K ;
Meinertz, T ;
Munzel, T .
CIRCULATION, 2003, 108 (05) :536-541
[8]   CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J].
Henn, V ;
Slupsky, JR ;
Gräfe, M ;
Anagnostopoulos, I ;
Förster, R ;
Müller-Berghaus, G ;
Kroczek, RA .
NATURE, 1998, 391 (6667) :591-594
[9]   Platelet CD40 ligand (CD40L) -: subcellular localization, regulation of expression, and inhibition by clopidogrel [J].
Hermann, A ;
Rauch, BH ;
Braun, M ;
Schrör, K ;
Weber, AA .
PLATELETS, 2001, 12 (02) :74-82
[10]   Acute systemic inflammation impairs endothelium-dependent dilatation in humans [J].
Hingorani, AD ;
Cross, J ;
Kharbanda, RK ;
Mullen, MJ ;
Bhagat, K ;
Taylor, M ;
Donald, AE ;
Palacios, M ;
Griffin, GE ;
Deanfield, JE ;
MacAllister, RJ ;
Vallance, P .
CIRCULATION, 2000, 102 (09) :994-999